Abnormal activation of HER2 is involved in development and progression of various types of cancer 2, 3; in particular, HER2 amplification is observed in 18–25% of human breast cancers 3, and is correlated with poor prognosis 4. This evidence concerns the gene ERBB2 and cancer.